|
1
|
Furnari FB, Fenton T, Bachoo RM, Mukasa A,
Stommel JM, et al: Malignant astrocytic glioma: genetics, biology,
and paths to treatment. Genes Dev. 21:2683–2710. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Omuro A and DeAngelis LM: Glioblastoma and
other malignant gliomas: a clinical review. JAMA. 310:1842–1850.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stupp R, Hegi ME, Gilbert MR and
Chakravarti A: Chemoradiotherapy in malignant glioma: standard of
care and future directions. J Clin Oncol. 25:4127–4136. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, et al: Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pegg AE: Repair of O(6)-alkylguanine by
alkyltransferases. Mutat Res. 462:83–100. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Roos WP and Kaina B: DNA damage-induced
cell death: from specific DNA lesions to the DNA damage response
and apoptosis. Cancer Lett. 332:237–248. 2013. View Article : Google Scholar
|
|
7
|
Kaina B, Christmann M, Naumann S and Roos
WP: MGMT: key node in the battle against genotoxicity,
carcinogenicity and apoptosis induced by alkylating agents. DNA
Repair (Amst). 6:1079–1099. 2007. View Article : Google Scholar
|
|
8
|
Sabharwal A and Middleton MR: Exploiting
the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer
therapy. Curr Opin Pharmacol. 6:355–363. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Day RS III, Ziolkowski CH, Scudiero DA,
Meyer SA, Lubiniecki AS, et al: Defective repair of alkylated DNA
by human tumour and SV40-transformed human cell strains. Nature.
288:724–7. 1980. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kondo N, Takahashi A, Ono K and Ohnishi T:
DNA damage induced by alkylating agents and repair pathways. J
Nucleic Acids. 2010:5435312010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fruehauf JP, Brem H, Brem S, Sloan A,
Barger G, et al: In vitro drug response and molecular markers
associated with drug resistance in malignant gliomas. Clin Cancer
Res. 12:4523–4532. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hermisson M, Klumpp A, Wick W, Wischhusen
J, Nagel G, et al: O6-methylguanine DNA methyltransferase and p53
status predict temozolomide sensitivity in human malignant glioma
cells. J Neurochem. 96:766–776. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dalerba P, Cho RW and Clarke MF: Cancer
stem cells: models and concepts. Annu Rev Med. 58:267–284. 2007.
View Article : Google Scholar
|
|
15
|
Singh SK, Clarke ID, Terasaki M, Bonn VE,
Hawkins C, et al: Identification of a cancer stem cell in human
brain tumors. Cancer Res. 63:5821–5828. 2003.PubMed/NCBI
|
|
16
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et
al: Glioma stem cells promote radioresistance by preferential
activation of the DNA damage response. Nature. 444:756–760. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang J, Wakeman TP, Lathia JD, Hjelmeland
AB, Wang XF, et al: Notch promotes radioresistance of glioma stem
cells. Stem Cells. 28:17–28. 2010.
|
|
18
|
Hardee ME, Marciscano AE, Medina-Ramirez
CM, Zagzag D, Narayana A, et al: Resistance of
glioblastoma-initiating cells to radiation mediated by the tumor
microenvironment can be abolished by inhibiting transforming growth
factor-β. Cancer Res. 72:4119–4129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Deleyrolle LP, Harding A, Cato K,
Siebzehnrubl FA, Rahman M, et al: Evidence for label-retaining
tumour-initiating cells in human glioblastoma. Brain.
134:1331–1343. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kang MK and Kang SK: Tumorigenesis of
chemotherapeutic drug-resistant cancer stem-like cells in brain
glioma. Stem Cells Dev. 16:837–847. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bleau AM, Huse JT and Holland EC: The
ABCG2 resistance network of glioblastoma. Cell Cycle. 8:2936–2944.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu G, Yuan X, Zeng Z, Tunici P, Ng H, et
al: Analysis of gene expression and chemoresistance of CD133+
cancer stem cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen J, Li Y, Yu TS, McKay RM, Burns DK,
et al: A restricted cell population propagates glioblastoma growth
after chemotherapy. Nature. 488:522–526. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Martinez-Rivera M and Siddik ZH:
Resistance and gain-of-resistance phenotypes in cancers harboring
wild-type p53. Biochem Pharmacol. 83:1049–1062. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu J, Zhang L, Hwang PM, Kinzler KW and
Vogelstein B: PUMA induces the rapid apoptosis of colorectal cancer
cells. Mol Cell. 7:673–682. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu J and Zhang L: PUMA, a potent killer
with or without p53. Oncogene. 27(Suppl 1): S71–S83. 2001.
View Article : Google Scholar
|
|
27
|
Ito H, Kanzawa T, Miyoshi T, Hirohata S,
Kyo S, et al: Therapeutic efficacy of PUMA for malignant glioma
cells regardless of p53 status. Hum Gene Ther. 16:685–698. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nagane M, Kobayashi K, Ohnishi A, Shimizu
S and Shiokawa Y: Prognostic significance of O6-methylguanine-DNA
methyltransferase protein expression in patients with recurrent
glioblastoma treated with temozolomide. Jpn J Clin Oncol.
37:897–906. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
He TC, Zhou S, da Costa LT, Yu J, Kinzler
KW and Vogelstein B: A simplified system for generating recombinant
adenoviruses. Proc Natl Acad Sci USA. 95:2509–2514. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mukai S, Kondo Y, Koga S, Komata T, Barna
BP, et al: 2-5A antisense telomerase RNA therapy for intracranial
malignant gliomas. Cancer Res. 60:4461–4467. 2000.PubMed/NCBI
|
|
31
|
Villano JL, Seery TE and Bressler LR:
Temozolomide in malignant gliomas: current use and future targets.
Cancer Chemother Pharmacol. 64:647–655. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Beier D, Schulz JB and Beier CP:
Chemoresistance of glio-blastoma cancer stem cells - much more
complex than expected. Mol Cancer. 10:1282008. View Article : Google Scholar
|
|
33
|
Koritzer J, Boxhammer V, Schafer A,
Shimizu T, Klampfl TG, et al: Restoration of sensitivity in
chemo-resistant glioma cells by cold atmospheric plasma. PLoS One.
8:e644982013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Francipane MG, Chandler J and Lagasse E:
Cancer stem cells: A moving target. Curr Pathobiol Rep. 1:111–118.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Medema JP: Cancer stem cells: the
challenges ahead. Nat Cell Biol. 15:338–344. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Smith ND, Rubenstein JN, Eggener SE and
Kozlowski JM: The p53 tumor suppressor gene and nuclear protein:
basic science review and relevance in the management of bladder
cancer. J Urol. 169:1219–1228. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hollstein M, Sidransky D, Vogelstein B and
Harris CC: p53 mutations in human cancers. Science. 253:49–53.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Petitjean A, Mathe E, Kato S, Ishioka C,
Tavtigian SV, et al: Impact of mutant p53 functional properties on
TP53 mutation patterns and tumor phenotype: lessons from recent
developments in the IARC TP53 database. Hum Mutat. 28:622–629.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Goh AM, Coffill CR and Lane DP: The role
of mutant p53 in human cancer. J Pathol. 223:116–126. 2011.
View Article : Google Scholar
|
|
40
|
Brosh R and Rotter V: When mutants gain
new powers: news from the mutant p53 field. Nat Rev Cancer.
9:701–713. 2009.PubMed/NCBI
|
|
41
|
Oren M and Rotter V: Mutant p53
gain-of-function in cancer. Cold Spring Harb Perspect Biol.
2:a0011072010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Haupt S, Berger M, Goldberg Z and Haupt Y:
Apoptosis - the p53 network. J Cell Sci. 116:4077–4085. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yu J, Yue W, Wu B and Zhang L: PUMA
sensitizes lung cancer cells to chemotherapeutic agents and
irradiation. Clin Cancer Res. 12:2928–2936. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ma J, Murphy M, O’Dwyer PJ, Berman E, Reed
K, et al: Biochemical changes associated with a multidrug-resistant
phenotype of a human glioma cell line with temozolomide-acquired
resistance. Biochem Pharmacol. 63:1219–1228. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Manero F, Gautier F, Gallenne T, Cauquil
N, Gree D, et al: The small organic compound HA14-1 prevents Bcl-2
interaction with Bax to sensitize malignant glioma cells to
induction of cell death. Cancer Res. 66:2757–2764. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tothova E, Fricova M, Stecova N, Kafkova A
and Elbertova A: High expression of Bcl-2 protein in acute myeloid
leukemia cells is associated with poor response to chemotherapy.
Neoplasma. 49:141–144. 2002.PubMed/NCBI
|
|
47
|
Gielen PR, Aftab Q, Ma N, Chen VC, Hong X,
et al: Connexin43 confers Temozolomide resistance in human glioma
cells by modulating the mitochondrial apoptosis pathway.
Neuropharmacology. 75:539–548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Eisele G and Weller M: Targeting apoptosis
pathways in glioblastoma. Cancer Lett. 332:335–345. 2013.
View Article : Google Scholar
|
